Our findings reveal a mechanism to explain ENaC upregulation in CF, not directly linked to CFTR defect but to the associated inflammation, and provide a further rationale for the use of ENaC inhibitors to treat CF patients (23). Here, CFTR is linked to cystic fibrosis.